Where can I find 600511.SS's financial statements?

China National Medicines Corporation Ltd. (600511.SS)'s full income statement, balance sheet, and cash flow statement are on this page in 10-K-style line-item format. Switch between the three statements via the pill toggle above the table.

How much history is available for 600511.SS?

China National Medicines Corporation Ltd. (600511.SS) statements are available back to its earliest filed 10-K — typically 10+ years of annual data and 40 quarters of quarterly data. Free-tier users see 5 years and 8 quarters; full history unlocks with a Pro account.

How often does 600511.SS update its statements?

China National Medicines Corporation Ltd. files a 10-K annually (full audited year-end statements) and 10-Q reports quarterly (unaudited interim statements). New filings are typically parsed and reflected on this page within 48 hours of SEC submission.

600511.SS

China National Medicines Corporation Ltd.

SHH·Drug Manufacturers, Specialty & Generic · Healthcare

¥27.47¥0.08−0.29%

Market cap¥20.73B·Market closed·Jul 23 3:29 AM UTC

CNY · values shown as reported

Line item	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025
Revenue	¥46.47B+15.1%	¥45.50B−2.1%	¥49.70B+9.2%	¥50.60B+1.8%	¥52.47B+3.7%
Cost of revenue	¥42.85B+15.1%	¥41.68B−2.7%	¥45.70B+9.7%	¥47.00B+2.8%	¥49.01B+4.3%
Gross profit	¥3.62B+15.5%	¥3.82B+5.4%	¥3.99B+4.6%	¥3.59B−10.0%	¥3.46B−3.7%
Research & development	¥55.75M+7.5%	¥67.00M+20.2%	¥71.20M+6.3%	¥73.71M+3.5%	¥69.31M−6.0%
General & administrative	¥388.32M+14.7%	¥408.26M+5.1%	¥442.45M+8.4%	¥451.69M+2.1%	¥67.88M−85.0%
Selling & marketing	¥939.88M−9.1%	¥956.13M+1.7%	¥962.09M+0.6%	¥804.65M−16.4%	¥274.52M−65.9%
SG&A (combined)	¥1.33B−3.3%	¥1.36B+2.7%	¥1.40B+2.9%	¥1.26B−10.6%	¥342.39M−72.7%
Other operating expenses	−¥210.25M−4.3%	−¥309.18M−47.1%	−¥428.44M−38.6%	−¥413.31M+3.5%	¥426.47M+203.2%
Total operating expenses	¥1.17B−4.0%	¥1.12B−4.4%	¥1.05B−6.7%	¥916.74M−12.5%	¥838.17M−8.6%
Operating income	¥2.45B+27.9%	¥2.69B+10.1%	¥2.94B+9.3%	¥2.68B−9.1%	¥2.62B−2.1%
Interest income	¥73.16M+18.7%	¥79.48M+8.6%	¥170.41M+114.4%	¥140.59M−17.5%	¥56.09M−60.1%
Interest expense	¥55.11M−69.0%	¥40.31M−26.9%	¥44.84M+11.2%	¥47.99M+7.0%	¥27.17M−43.4%
Other income / (expense), net	−¥2.47M−159.8%	−¥7.04M−185.1%	−¥13.47M−91.4%	−¥23.81M−76.8%	−¥21.52M+9.6%
Income before tax	¥2.44B+27.5%	¥2.69B+9.9%	¥2.93B+9.0%	¥2.65B−9.5%	¥2.60B−2.0%
Income tax expense	¥516.30M+26.5%	¥559.18M+8.3%	¥596.42M+6.7%	¥523.83M−12.2%	¥510.74M−2.5%
Net income	¥1.75B+26.9%	¥1.96B+12.0%	¥2.15B+9.3%	¥2.00B−6.8%	¥2.00B−0.2%

EPS (basic)	¥2.32+26.8%	¥2.60+12.1%	¥2.84+9.2%	¥2.65−6.7%	¥2.65+0.0%
EPS (diluted)	¥2.32+26.8%	¥2.60+12.1%	¥2.84+9.2%	¥2.65−6.7%	¥2.65+0.0%
Weighted avg shares (basic)	754,502,998	754,502,998	754,502,998	754,508,636	754,513,308
Weighted avg shares (diluted)	754,502,998	754,502,998	754,502,998	754,508,636	754,513,308

Depreciation & amortization	¥100.10M−3.2%	¥103.86M+3.8%	¥113.09M+8.9%	¥110.03M−2.7%	¥238.22M+116.5%
EBITDA	¥2.15B+29.1%	¥2.42B+12.4%	¥2.49B+2.6%	¥2.21B−10.9%	¥2.87B+29.4%

Frequently Asked Questions About 600511.SS

Where can I find 600511.SS's financial statements?: China National Medicines Corporation Ltd. (600511.SS)'s full income statement, balance sheet, and cash flow statement are on this page in 10-K-style line-item format. Switch between the three statements via the pill toggle above the table.
How much history is available for 600511.SS?: China National Medicines Corporation Ltd. (600511.SS) statements are available back to its earliest filed 10-K — typically 10+ years of annual data and 40 quarters of quarterly data. Free-tier users see 5 years and 8 quarters; full history unlocks with a Pro account.
How often does 600511.SS update its statements?: China National Medicines Corporation Ltd. files a 10-K annually (full audited year-end statements) and 10-Q reports quarterly (unaudited interim statements). New filings are typically parsed and reflected on this page within 48 hours of SEC submission.

Line item

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Trend

Revenue

¥46.47B+15.1%

¥45.50B−2.1%

¥49.70B+9.2%

¥50.60B+1.8%

¥52.47B+3.7%

Cost of revenue

¥42.85B+15.1%

¥41.68B−2.7%

¥45.70B+9.7%

¥47.00B+2.8%

¥49.01B+4.3%

Gross profit

¥3.62B+15.5%

¥3.82B+5.4%

¥3.99B+4.6%

¥3.59B−10.0%

¥3.46B−3.7%

Research & development

¥55.75M+7.5%

¥67.00M+20.2%

¥71.20M+6.3%

¥73.71M+3.5%

¥69.31M−6.0%

General & administrative

¥388.32M+14.7%

¥408.26M+5.1%

¥442.45M+8.4%

¥451.69M+2.1%

¥67.88M−85.0%

Selling & marketing

¥939.88M−9.1%

¥956.13M+1.7%

¥962.09M+0.6%

¥804.65M−16.4%

¥274.52M−65.9%

SG&A (combined)

¥1.33B−3.3%

¥1.36B+2.7%

¥1.40B+2.9%

¥1.26B−10.6%

¥342.39M−72.7%

Other operating expenses

−¥210.25M−4.3%

−¥309.18M−47.1%

−¥428.44M−38.6%

−¥413.31M+3.5%

¥426.47M+203.2%

Total operating expenses

¥1.17B−4.0%

¥1.12B−4.4%

¥1.05B−6.7%

¥916.74M−12.5%

¥838.17M−8.6%

Operating income

¥2.45B+27.9%

¥2.69B+10.1%

¥2.94B+9.3%

¥2.68B−9.1%

¥2.62B−2.1%

Interest income

¥73.16M+18.7%

¥79.48M+8.6%

¥170.41M+114.4%

¥140.59M−17.5%

¥56.09M−60.1%

Interest expense

¥55.11M−69.0%

¥40.31M−26.9%

¥44.84M+11.2%

¥47.99M+7.0%

¥27.17M−43.4%

Other income / (expense), net

−¥2.47M−159.8%

−¥7.04M−185.1%

−¥13.47M−91.4%

−¥23.81M−76.8%

−¥21.52M+9.6%

Income before tax

¥2.44B+27.5%

¥2.69B+9.9%

¥2.93B+9.0%

¥2.65B−9.5%

¥2.60B−2.0%

Income tax expense

¥516.30M+26.5%

¥559.18M+8.3%

¥596.42M+6.7%

¥523.83M−12.2%

¥510.74M−2.5%

Net income

¥1.75B+26.9%

¥1.96B+12.0%

¥2.15B+9.3%

¥2.00B−6.8%

¥2.00B−0.2%

EPS (basic)

¥2.32+26.8%

¥2.60+12.1%

¥2.84+9.2%

¥2.65−6.7%

¥2.65+0.0%

EPS (diluted)

¥2.32+26.8%

¥2.60+12.1%

¥2.84+9.2%

¥2.65−6.7%

¥2.65+0.0%

Weighted avg shares (basic)

754,502,998

754,508,636

754,513,308

Weighted avg shares (diluted)

754,502,998

754,508,636

754,513,308

Depreciation & amortization

¥100.10M−3.2%

¥103.86M+3.8%

¥113.09M+8.9%

¥110.03M−2.7%

¥238.22M+116.5%

EBITDA

¥2.15B+29.1%

¥2.42B+12.4%

¥2.49B+2.6%

¥2.21B−10.9%

¥2.87B+29.4%